PURE Bioscience’s PURE Hard Surface Launched to Corporate and Government Customers through Office Depot’s Business Solutions

  PURE Bioscience’s PURE Hard Surface Launched to Corporate and Government
  Customers through Office Depot’s Business Solutions Division

Business Wire

SAN DIEGO -- January 22, 2013

PURE Bioscience, Inc. (NASDAQ: PURE), creator of the patented silver
dihydrogen citrate (SDC) antimicrobial, today announced that PURE Hard Surface
disinfectant and food contact surface sanitizer is now available to corporate
and government customers through Office Depot’s Business Solutions Division
(BSD). This new product offering is part of a current flu season marketing
campaign as well as an ongoing sales program targeting corporate and
government breakrooms.

James McClenahan, Vice President of Sales for PURE Bioscience, stated, “We are
excited about this opportunity with Office Depot’s Business Solutions Division
and the expected national exposure for PURE Hard Surface through the
division’s 2,200 salespeople. We believe PURE Hard Surface disinfectant is a
great addition to Office Depot’s cleaning and breakroom initiative as it is a
uniquely powerful and responsible new product offering during this year’s
growing influenza epidemic.”

Michael L. Krall, President and CEO added, “I’d like to congratulate our team
on this early success in our commercialization strategy for our proprietary
PURE Hard Surface disinfectant through established regional and national
distribution channels. We continue our focus on gaining entry into corporate,
government and medical facilities as well as in the food service and food
processing markets.”

About PURE Hard Surface

US EPA registered PURE Hard Surface disinfectant and food contact surface
sanitizer provides an unparalleled combination of high efficacy and low
toxicity with 30-second bacterial and viral kill times and 24-hour residual
protection. SDC-based PURE Hard Surface completely kills resistant pathogens
like MRSA and Carbapenem-resistant Klebsiella pneumoniae (NDM-1) and also
effectively eliminates dangerous fungi and viruses including HIV, Hepatitis B,
Hepatitis C, Norovirus, Influenza A, Avian Influenza and H1N1 as well as
hazardous food pathogens such as E. coli, Salmonella and Campylobacter. PURE
Hard Surface delivers powerful broad-spectrum efficacy while remaining
classified as least-toxic (Category IV) by the US EPA, and its active
ingredient, SDC, has been determined Generally Recognized as Safe (GRAS) for
use as a biocide on food processing equipment, machinery and utensils.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience
products that provide solutions to numerous global health challenges,
including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity
bioscience technologies, including its silver dihydrogen citrate-based
antimicrobials, represent innovative advances in diverse markets and lead
today’s global trend toward industry and consumer use of “green” products
while providing competitive advantages in efficacy and safety. Patented SDC is
an electrolytically generated source of stabilized ionic silver, which
formulates well with other compounds. As a platform technology, SDC is
distinguished from competitors in the marketplace because of its superior
efficacy, reduced toxicity and the inability of bacteria to form a resistance
to it. PURE is headquartered in El Cajon, California (San Diego metropolitan
area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute “forward-looking”
statements, usually containing the words “believe,” “estimate,” “project,”
“expect” or similar expressions. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements inherently involve risks and uncertainties
that could cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such differences
include, but are not limited to, the Company’s cash position and liquidity
requirements, the Company’s failure to implement or otherwise achieve the
benefits of its strategic initiatives, acceptance of the Company's current and
future products and services in the marketplace, the ability of the Company to
develop effective new products and receive regulatory approvals of such
products, competitive factors, dependence upon third-party vendors, and other
risks detailed in the Company's periodic report filings with the Securities
and Exchange Commission. By making these forward-looking statements, the
Company undertakes no obligation to update these statements for revisions or
changes after the date of this release.

Contact:

PURE Bioscience Investor Contact:
LHA
Don Markley, Senior Vice President
(310) 691-7100
or
PURE Business Contact:
James McClenahan, VP Sales
(619) 596-8600, ext. 145
jmcclenahan@purebio.com
 
Press spacebar to pause and continue. Press esc to stop.